Bimatoprost Eye Drops

Buy Bimatoprost Eye Drops

Bimatoprost 0.03% 3ml 1bottle $36.99 $36.99 per bottle Buy Now
Bimatoprost 0.03% 3ml 2bottles $65.99 $32.99 per bottle Buy Now
Bimatoprost 0.03% 3ml 4bottles $120.99 $30.25 per bottle Buy Now
Bimatoprost 0.03% 3ml 6bottles $173.99 $29.00 per bottle Buy Now

Bimatoprost is a strong ophthalmic hypotensive agent. This is a synthetic prostamide structurally belonged to PGF2 alpha, which does not act through the known receptors. It selectively simulates the effects of newly discovered biosynthesized substances – prostamides. However, the structure of this receptor has not yet been defined.

Bimatoprost effect is oriented on the reduction in intraocular pressure in humans by increasing the outflow of aqueous humor through the trabecular meshwork and uveoscleral outflow. IOP reduction is observed about 4 hours after the first application and the maximum effect is reached after about 8–12 hours. The effect lasts for at least 24 hours.


  • Reduction of increased IOP in open-angle glaucoma and ophthalmic hypertension in adults (as monotherapy or in combination with beta-blockers).
  • Treatment of eyelashes’ hypotrichosis (insufficient growth of eyelashes).


  • Hypersensitivity;
  • Pregnancy;
  • Breastfeeding period;
  • Age up to 18 years.

Pregnancy and lactation

The FDA characterizes these eye drops as C.

There is no data from clinical studies on the use of bimatoprost in pregnant women. According to animal studies, reproductive toxicity has been demonstrated when used in high doses that are toxic to the mother’s body.

In animal studies, miscarriages were observed at oral administration of bimatoprost at a dose that was 33–97 times higher than that recommended for local use. When applied at a dose 41 times higher than therapeutic, there was a reduction in terms of gestation, an increase in the frequency of fetal death, and a decrease in the body weight of newborns.

The use of bimatoprost during pregnancy in the absence of strict indications is not recommended.

It is not known whether these eye drops can penetrate human breast milk. Animal studies have shown that bimatoprost is excreted in breast milk. If it is necessary to use this remedy during the breastfeeding period, it is necessary to make a decision to discontinue breastfeeding or therapy with bimatoprost, taking into account the benefit of breastfeeding for the child and the need for therapy for the mother.

Side effects

  • Nervous system: often – headache; infrequently – dizziness.
  • Organs of vision: very often – injection of the conjunctival vessels, itching in the eyes, the growth of eyelashes; often – superficial punctate keratitis, corneal erosion, burning in the eyes, eye irritation, allergic conjunctivitis, blepharitis, reduced visual acuity, dry eye mucosa, eyelid redness, eye pain, photophobia, eye secretions, blurred vision, eyelid itching, asthenopia, conjunctival edema, foreign body sensation in the eye, eye pain, tearing, blurred vision, increased iris pigmentation, eyelash darkening; infrequently – hemorrhagic disorders of the retina, uveitis, cystic macular edema, iritis, blepharospasm, eyelid retraction, periorbital erythema; with unknown frequency – enophthalmos.
  • Vessels system: often – hypertension.
  • Skin and subcutaneous tissues: infrequently – hirsutism.
  • General disorders and disorders at the injection site: infrequently – asthenia.
  • The data of laboratory and instrumental studies: often – deviation from the norm of biochemical parameters of the hepatic function.

In very rare cases, corneal calcification was observed when phosphate-containing eye drops were used by patients with concomitant significant corneal damage.


Special studies of interaction with other drugs have not been carried out. No interaction is expected in the human body since systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/ml) after local application of these eye drops in ophthalmology.

In clinical studies, this remedy was used in conjunction with several different beta-blockers for local use in ophthalmology, but no interaction was identified.

The simultaneous use of these drops and other antiglaucoma drugs, except for ophthalmic beta-blockers, has not been studied in the course of studies of the effectiveness and safety of combination therapy.

There was a decrease in the hypotensive effect of Bimatoprost in the form of eye drops when it is used together with other PG analogs in the treatment of ophthalmic hypertension or glaucoma.


There were no cases of overdose when applied locally. In case of overdose, the therapy should be symptomatic and supportive.